Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CABA
Strong SellSinkerCabaletta Bio, Inc. · Healthcare · United States · $529M · Avg Vol: $13M/d
COMPANY DESCRIPTION
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for patients with autoimmune diseases. The company's competitive advantage is its proprietary CABA™ platform, which designs T cell therapies to precisely target and eliminate disease-causing B cells. Cabaletta aims to offer potentially transformative, curative treatments for chronic autoimmune conditions by inducing deep and durable remission.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.80 | -0.33 | -0.47 | -0.73 | -2.10 | — | -1.38 | -1.36 | -1.48 | — |
| Shares | 28.9M | 163.1M | 163.1M | 163.1M | 100.5M | +247.4% | — | — | — | — |
| Debt | 0 | 5.1M | 5.0M | 15.6M | 27.1M | 74.1% | 25.7M | — | — | — |
| Equity | 118.0M | 104.5M | 236.2M | 152.3M | 112.1M | -1.3% | — | — | — | — |
| Op CF | -34.1M | -46.4M | -53.5M | -88.2M | -131.1M | — | -153.9M | — | — | — |
| Inv CF | 6.0M | -27.2M | -22.5M | 47.3M | -50.3M | — | — | — | — | — |
| Fin CF | 48.9M | 33.0M | 187.6M | 11.7M | 100.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CABA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CABA | Cabaletta Bio, Inc.(you) | $529M | 11 | Strong Sell |
| EIKN | Eikon Therapeutics, Inc. | $595M | 10 | Strong Sell |
| KYTX | Kyverna Therapeutics, Inc. | $518M | 7 | Strong Sell |
| RCKT | Rocket Pharmaceuticals, Inc. | $424M | 11 | Strong Sell |
| EVMN | Evommune, Inc. | $480M | 8 | Strong Sell |
| BLSM | BlossomHill Therapeutics, Inc. | $569M | 7 | Strong Sell |
| GALT | Galectin Therapeutics Inc. | $405M | 11 | Strong Sell |
| EDIT | Editas Medicine, Inc. | $485M | 15 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $698M | 10 | Strong Sell |
| CTMX | CytomX Therapeutics, Inc. | $699M | 12 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%